SEARCH

SEARCH BY CITATION

References

  • 1
    Jones DB, Howden CW, Burget DW, et al. Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut 1987; 28: 11207.
  • 2
    Burget DW, Stephen G, Chiverton SG, et al. Is there an optimal degree of acid suppression for healing of duodenal ulcer? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99: 34551.
  • 3
    Bell NJ, Burget D, Howden C, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1993; 51(Suppl. 1): 5967.
  • 4
    Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798810.
  • 5
    Bell NJ & Hunt RH. Time to maximum effect of lansoprazole on gastric pH in normal male volunteers. Aliment Pharmacol Ther 1996; 10: 897904.
  • 6
    Blum RA, Shi H, Karol M, et al. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther 1997; 19: 101323.
  • 7
    Takeda H, Hokari K, Asaka M. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring. J Clin Gastroenterol 1995; 20(Suppl. 1): S79.
  • 8
    Bruley des Varannes S, Levy P, Lartigue S, et al. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion, and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994; 8(3): 30914.
  • 9
    Dammann HG, Fuchs W, Richter G, et al. Influence of lansoprazole 15 mg and omeprazole 20 mg and 40 mg on meal-stimulated gastric acid secretion. Aliment Pharmacol Ther 1997; 11: 35964.
  • 10
    Tolman KG. Comparison of the effects of lansoprazole and omeprazole on 24-hour gastric pH in normal male volunteers. J Clin Gastroenterol 1997; 24: 6570.DOI: 10.1097/00004836-199703000-00003
  • 11
    Hussein Z, Granneman GR, Mukherjee D, et al. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol 1993; 36: 3918.
  • 12
    Regardh GG. Pharmacokinetics and metabolism of omeprazole in man. Scand J Gastroenterol 1991; 21(Suppl. 118): 99104.
  • 13
    Chun AHC, Eason CJ, Shi HH, et al. Lansoprazole: an alternative method of administration of a capsule dosage formulation. Clin Ther 1995; 17: 4417.
  • 14
    Chun AHC, Shi HH, Achari R, et al. Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube. Clin Ther 1996; 18: 83342.
  • 15
    Sharma VK, Ugheoke EA, Vasudeva R, et al. The pharmacodynamics of lansoprazole administered via gastrostomy as intact, non-encapsulated granules. Aliment Pharmacol Ther 1998; 12: 11714.
  • 16
    Zimmermann A, Walters JK, Katona B, et al. Alternative methods of proton pump inhibitor administration. Consult Pharm 1997; 12: 9908.
  • 17
    Sharma VK, Vasudeva R, Howden CW. A study of the effects of per-gastrostomy administration of an alkaline suspension of omeprazole on intragastric acidity. Aliment Pharmacol Ther 1999; 13: 10916.
  • 18
    Sharma VK, Heinzelmann EJ, Steinberg EN, et al. Nonencapsulated intact granule omeprazole is effective in gastric acid suppression. Am J Gastroenterol 1997; 92: 84851.
  • 19
    Sharma VK. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole. Am J Health Syst Pharm 1999; 56(23 Suppl. 4): S1821.
  • 20
    Sharma VK, Vasudeva R, Howden CW. Simplified lansoprazole suspension—a liquid formulation of lansoprazole—effectively suppresses intragastric acidity when administered through a gastrostomy. Am J Gastroenterol 1999; 94(7): 18137.
  • 21
    Pisegna JR, Martin P, Mckeand W, et al. Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose–response study. Am J Gastroenterol 1999; 94: 287480.
    Direct Link:
  • 22
    Hartmann M, Ehrlich A, Fuder H, et al. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. Aliment Pharmacol Ther 1998; 12: 102732.DOI: 10.1046/j.1365-2036.1998.00406.x
  • 23
    SAS Institute. The GLM Procedure. In: SAS/STAT User’s Guide, Vol 2, Version 6, 4th edn. Cary, NC: SAS Institute, 1990: 891–996.
  • 24
    Florent C & Forestier S. Twenty-four hour monitoring of intragastric acidity: comparison between lansoprazole 30 mg and pantoprazole 40 mg. Eur J Gastroenterol Hepatol 1997; 9: 195200.
  • 25
    Thomson A, Appelman S, Sridhar S, et al. Lansoprazole or pantoprazole: which PPI provides faster and more profound acid suppression? Gastroenterol 1999; 116: A334A334(Abstract).
  • 26
    Huang JW, Goldwater DR, Thomson ABR, et al. Lansoprazole achieves faster control of intragastric acidity than pantoprazole. Am J Gastroenterol 1999; 94: A129A129(Abstract).
  • 27
    Freston JW, Chiu YL, Pan WJ, et al. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. Am J Gastroenterol 2001; 96: 205865.
    Direct Link:
  • 28
    Doan TT, Wang Q, Griffin JS, et al. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. Am J Health Syst Pharm 2001; 58: 151219.